Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ketone showdown: which supplement wins in the body?

NCT ID NCT07289165

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how healthy adults absorb and process three different ketone supplements (monoester, tri-ester, and salt). Researchers will measure ketone levels in the blood and check for any stomach discomfort or side effects. The goal is simply to gather information, not to treat or prevent any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Provide voluntary signed and dated informed consent. * Be in good health as determined by medical history and routine blood chemistries. * Age between 30 and 70 yr (inclusive). * Body Mass Index of 25-34.9 (inclusive). * Body weight of at least 120 pounds. * Normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility. * Normal seated, resting heart rate (\<90 per minute). * Willing to duplicate and record their previous 24-hour diet, refrain from caffeine, alcohol and exercise for 24 hours prior to each visit, and fast for 10 hours prior to each visit. * Subject agrees to maintain existing dietary and physical activity patterns throughout the study period. * Subject is willing and able to comply with the study protocol. Exclusion Criteria: * Individuals using any kind of GLP-1 medications. * Individuals who are determined to have liver, renal, cardiovascular, neurological, or other metabolic disease. * History or presence of diabetes, prediabetes or endocrine disorder. * Use of any dietary supplements or medications which may confound the study or its endpoints (e.g., fish oil, choline donors, gingko biloba, phosphatidylserine, huperzine A, etc.). * Alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months. * Current nicotine use \> 100 mg/day. * History of hyperparathyroidism or an untreated thyroid condition. * History of malignancy in the previous 5 years, except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). * History of chronic psychiatric conditions (e.g., bipolar, schizophrenia, PTSD, depression, etc.). * History of brain disorders \[e.g., stroke, MS, Parkinson's, history of TBI or epilepsy, migraine (\>1 migraine per month), etc.\]. * Prior gastrointestinal bypass surgery (Lapband), etc. * Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, Inflammatory bowel syndrome (IBS), Inflammatory bowel disease (IBD; e.g., Crohn's, ulcerative colitis), diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU). * Chronic inflammatory condition (e.g., rheumatoid arthritis, Lupus, HIV/AIDS, etc.). * Previous medical diagnosis of asthma, gout, or fibromyalgia. * Currently following a low-carbohydrate, keto type diet, or practicing an intermittent fasting lifestyle (\>14 hours of fasting). * Subjects that have donated blood or plasma within the previous week. * Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Women who participate in this study must agree to the use of contraception for the duration of the study and any woman that is sexually active will have to take pregnancy test prior to enrolling with a negative result. Women of childbearing age (any woman prior to menopause) regardless of their use of contraception will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent. * Known sensitivity to any ingredient in the test formulations as listed in the product label. * Currently participating in another research study with an investigational product or have been in another research study in the past 30 days. * Clinically significant abnormal laboratory results at screening. * Any other conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CAHS

    Canfield, Ohio, 44406, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.